NCT05088512

Brief Summary

To research for a genetic marker of bronchial asthma, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with bronchial asthma and normal control will be performed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 25, 2021

Completed
27 days until next milestone

First Posted

Study publicly available on registry

October 22, 2021

Completed
1 day until next milestone

Study Start

First participant enrolled

October 23, 2021

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2023

Completed
Last Updated

March 14, 2023

Status Verified

March 1, 2023

Enrollment Period

1.2 years

First QC Date

September 25, 2021

Last Update Submit

March 13, 2023

Conditions

Bronchial AsthmaGenome Wide Association Studies

Keywords

Bronchial AsthmaGenome Wide Association Studies

Outcome Measures

Primary Outcomes (1)

  • number of SNPs associated with bronchial asthma

    Using SNPsto identify candidate genes associate with bronchial asthma

    1 year

Study Arms (2)

Experimental group:

Patients with bronchial asthma

Genetic: SNP analysis of the DNA

Control group

Patients without bronchial asthma

Genetic: SNP analysis of the DNA

Interventions

SNP analysis of the DNAGENETIC

SNP analysis of the DNA obtained from peripheral blood sample

Control groupExperimental group:

Eligibility Criteria

Age5 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Persons with bronchial asthma confirmed by a doctor

You may qualify if:

  • Persons with bronchial asthma confirmed by a doctor;
  • The age of the patients is from 5 to 60 years;
  • Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs.
  • Persons who are able and willing to provide written informed consent;
  • Persons capable and willing to comply with the research protocol;

You may not qualify if:

  • Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
  • Pregnant or lactating women;
  • Tuberculosis of any localization in the active phase and in history;
  • Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
  • Severe and decompensated course of endocrine diseases;
  • Autoimmune diseases;
  • Systemic diseases;
  • Oncological diseases;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kazakhstan

Almaty, 050020, Kazakhstan

Location

Biospecimen

Retention: SAMPLES WITH DNA

blood

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Project manager

Study Record Dates

First Submitted

September 25, 2021

First Posted

October 22, 2021

Study Start

October 23, 2021

Primary Completion

January 20, 2023

Study Completion

January 20, 2023

Last Updated

March 14, 2023

Record last verified: 2023-03

Locations

KA(1)